PharmaVision offers a comprehensive choice of high quality, insightful reports which identify key trends, future innovations, and growth opportunities. Our reports cover the life science arena including pharmaceuticals, healthcare, diagnostics, drug delivery, emerging R&D technologies and consumer nutrition.
Actelion acquired by Johnson & Johnson for $30 billion ($280 per share in cash). The acquisition will enable J&J to gain access to Actelion's PAH franchise which includes Opsumit, Uptravi, Tracleer, Veletri and Ventavis. It will also lead to a spin out of Actelion's drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company R&D NewCo.
During the last decade the pharmaceutical industry has been looking towards the emerging economies to expand its global footprint and drive future growth. This white paper focuses on the potential opportunities for investment in the Middle East, particularly with respect to Bahrain, Saudi Arabia and the United Arab Emirates.